HANSOH PHARMAC. HD-00001 (3KY) — Capital Reinvestment Ratio
HANSOH PHARMAC. HD-00001 (3KY) has a Capital Reinvestment Ratio of 0.07x as of December 2025, meaning it reinvests 0% of its operating cash flow (€6.74 Billion) in capital expenditures (€489.46 Million). See HANSOH PHARMAC. HD-00001 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
HANSOH PHARMAC. HD-00001 Capital Reinvestment Ratio (2021–2025)
This chart tracks HANSOH PHARMAC. HD-00001's Capital Reinvestment Ratio across 5 annual periods. See 3KY FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Capital Reinvestment Ratio for HANSOH PHARMAC. HD-00001 (2021–2025)
Year-by-year Capital Reinvestment Ratio for HANSOH PHARMAC. HD-00001 from 2021 to 2025. For the full cash flow conversion analysis, see cash efficiency ratio of HANSOH PHARMAC. HD-00001.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.07x | €6.74 Billion | €489.46 Million | ▼ -46.6% |
| 2024 | 0.14x | €3.86 Billion | €524.93 Million | ▲ +16.8% |
| 2023 | 0.12x | €3.12 Billion | €362.52 Million | ▲ +9.3% |
| 2022 | 0.11x | €2.74 Billion | €291.82 Million | ▼ -42.3% |
| 2021 | 0.18x | €2.58 Billion | €475.44 Million | — |